Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

GC Corporation Signs Definitive Agreement to Acquire US CDMO BioCentriq, Enhancing Global Capabilities

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

GC Corporation (KOSPI: 005250), the holding (system) company for GC group in South Korea with major operating companies in across healthcare sectors, today announced that it has signed a definitive agreement to acquire 100% of the shares of BioCentriq, Inc., a pioneering US-based contract development and manufacturing organization (CDMO) that designs and develops scalable cell and gene technologies. This cross-border acquisition broadens GC companies’ capabilities in scaling CDMO platforms.

Founded in 2019 as a New Jersey Innovation Institute company, BioCentriq is well-positioned in the potentially $ 40 billion addressable market, end-to-end CDMO for cell and gene therapy process development and clinical manufacturing with cGMP-grade clinical manufacturing facility across locations in New Jersey. The company manufactures autologous and allogeneic cell therapies and gene therapies and specializes in viral vector production, cell and viral banking, and upstream and downstream processing.

“BioCentriq’s unique expertise in the rapidly growing cell and gene therapy CDMO will be a transformative addition to our business that we believe will accelerate our growth, with additional expansion projects underway adjacent to current BioCentriq facilities.” said Yong-Jun Huh, president of GC. “We are thrilled to team up with BioCentriq’s incredibly talented team.”

Going forward BioCentriq will operate in a mode similar to other GC companies, wherein each company maintains its individual culture and identity while sharing best practices.

Raymond James is acting as GC’s advisor on this transaction.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine